Coho Partners Ltd. lowered its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 28.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 312,153 shares of the company's stock after selling 122,392 shares during the period. Cencora comprises about 5.2% of Coho Partners Ltd.'s holdings, making the stock its largest holding. Coho Partners Ltd. owned approximately 0.16% of Cencora worth $86,807,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Hoey Investments Inc. purchased a new stake in shares of Cencora during the first quarter valued at approximately $28,000. Banque Transatlantique SA purchased a new stake in shares of Cencora in the 4th quarter worth about $29,000. SBI Securities Co. Ltd. bought a new position in shares of Cencora in the 4th quarter worth about $30,000. Vermillion Wealth Management Inc. bought a new position in shares of Cencora in the 4th quarter worth about $38,000. Finally, OFI Invest Asset Management purchased a new position in Cencora during the 4th quarter valued at about $41,000. Institutional investors own 97.52% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. UBS Group raised their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Citigroup raised their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Bank of America increased their price objective on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Finally, Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average price target of $306.91.
Get Our Latest Stock Report on Cencora
Insider Buying and Selling at Cencora
In other news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,126 shares of company stock worth $9,475,106. Insiders own 10.80% of the company's stock.
Cencora Stock Performance
COR stock traded down $0.59 during trading on Monday, reaching $293.08. The stock had a trading volume of 1,516,711 shares, compared to its average volume of 1,519,921. The firm has a market cap of $56.80 billion, a PE ratio of 34.00, a PEG ratio of 1.45 and a beta of 0.58. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The stock's 50 day moving average is $289.16 and its two-hundred day moving average is $263.77. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35.
Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter last year, the firm posted $3.80 earnings per share. The firm's revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.
Cencora Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is currently 25.52%.
Cencora Company Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
